New trial: can targeted radiation boost survival in patients with up to 10 metastases?
NCT ID NCT05717166
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase III trial tests whether adding stereotactic ablative radiotherapy (SABR) to standard treatment (chemotherapy, hormone therapy, or palliative radiation) improves survival in adults with 1 to 10 metastatic tumors and an active primary cancer. About 180 participants will be randomly assigned to standard care alone or standard care plus SABR. The study aims to see if this approach extends life and preserves quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Stereotactic ablative radiotherapy (SABR)
What this could lead to
If successful, this could show that adding precise, high-dose radiation to standard treatment helps people with limited metastatic cancer live longer and maintain quality of life.
What could go wrong
This is a relatively early phase III trial with 180 participants, so results may not apply to all cancer types. SABR can cause side effects like fatigue or damage to nearby organs, and it may not improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BC Cancer - Centre for the North
NOT_YET_RECRUITINGPrince George, British Columbia, V2M 7E9, Canada
Contact
-
BC Cancer - Vancouver
RECRUITINGVancouver, British Columbia, V5Z 4C2, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre Hospitalier de l'Université de Montréal-CHUM
RECRUITINGMontreal, Quebec, H2X 0C1, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
London Regional Cancer Program of the Lawson Health Research Institute
RECRUITINGLondon, Ontario, N6A 5W9, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Universitätsspital Zürich
RECRUITINGZurich, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••